Thus, the balance between benefit and risk may vary between a randomized scientific trial and encounter in a nontrial, routine clinical treatment setting. Therefore, encounters from clinical practice provide essential complementary info,’ the authors write.. Anticoagulant fondaparinux lowers threat of major bleeding events, death in heart attack patients Patients who also experienced a particular type of coronary attack who all received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in a healthcare facility and after six months compared to patients who have received low-molecular-pounds heparin , although both groups had similar rates of subsequent heart attack or stroke, according to a report in the February 17 issue of JAMA.Related StoriesIU-led scientists discover brand-new gene that raises Alzheimer's disease riskRestoring memory in aging miceCollaborative approach may swiftness discovery of new preventive remedies for Alzheimer's diseaseIn a parallel study, 23 healthy human topics, age 18 to 50 without medical disease and without previous background of anti-depressant treatment, were administered 60 mg citalopram, roughly equivalent to the dose found in mice. The double-blind study showed that citalopram was associated with a 38 % lower A-beta concentration over the 37-hour screening period versus placebo, and demonstrated a decrease in newly-created A-beta in the citalopram-treated group versus the control group.